All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Not reported Terminated | 2008-006765-82 | Preventive therapy for multidrug-resistant tuberculosis: a multicentre clincal trial. | 2014-01-29 | due-trials |
Reported results | 2009-016697-32 | PRotease-Inhibitors MOnotherapy Strategies as maintenance therapy in persons with fully suppressed HIV replication: results from an open-label randomized comparative trial (PRIMO Trial) | 2014-10-27 | due-trials |
Completed, but no date Terminated | 2009-016705-42 | Pilot study on efficacy of a simplification strategy from DRV/r 600/100 mg BID to DRV/r 800/100mg QD + OBT in HIV-positive patients HAART-experienced with virological response. | bad-data | |
Completed, report not yet due | 2010-023245-30 | Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis | 2024-12-23 | not-yet-due |
Completed, report not yet due | 2011-004038-33 | Non-inferiority,randomized clinical trial to evaluate the efficacy and the safety of the use of fixed-dose combination efavirenz/tenofovir/emtricitabine (Atripla) administered in alternate days versu... | 2024-12-02 | not-yet-due |
Completed, but no date Terminated | 2011-004693-29 | Pegylated interferon alfa-2a USE FOR CONTROLLING virological rebound after suspension of antiretroviral treatment IN PATIENTS WITH CHRONIC HIV INFECTION USO DELL’INTERFERONE ALFA-2A PEGHILATO PER ... | bad-data | |
Completed, report not yet due | 2011-005270-35 | HIV-infected pregnant women treated with HAART: registry of pharmacokinetic parameters of new and commonly used antiretrovirals DONNE CON INFEZIONE DA HIV TRATTATE CON HAART: REGISTRO DEI PARAMETR... | 2024-12-23 | not-yet-due |
Completed, but no date | 2014-003874-17 | Antiretroviral Pre-exposure prophylaxis for natural conception (PrEP-C) in serodiscordant female partners of HIV-infected men in sustained virologic suppression Profilassi antiretrovirale pre-espo... | bad-data | |
Not reported | 2016-002006-39 | Study on Efficacy and safety of an early proactive Switch To ElvitegraviR/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in patients with a primary HIV-1 infection Study on Efficacy and... | 2022-05-27 | due-trials |
Completed, report not yet due | 2018-003880-79 | Efficacy and safety of the switch from Efavirenz / emtricitabine / tenofovir difumarate taken once daily or alternate days to Bictegravir / emtricitabine / tenofovir alafenamide in HIV + virologically... | 2024-09-19 | not-yet-due |
Other | 2019-002514-40 | Phase II study on the safety and efficacy of cysteamine in association with standard tuberculosis therapy for the treatment of patients with pulmonary tuberculosis: a new therapy for tuberculosis dire... | not-yet-due | |
Completed, but no date | 2019-003614-14 | Feasibility, efficacy and safety of rapid (within 7 days from HIV diagnosis) antiretroviral initiation strategy based on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-infected naïve... | bad-data | |
Not reported | 2020-001390-76 | A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients... | 2023-03-30 | due-trials |
Reported results Terminated | 2020-001472-14 | AN OPEN-LABEL, RANDOMIZED, PARALLEL-ARM STUDY INVESTIGATING THE EFFICACY AND SAFETY OF INTRAVENOUS ADMINISTRATION OF PAMREVLUMAB VERSUS STANDARD OF CARE IN PATIENTS WITH SARS-COV-2 INFECTION | 2022-05-16 | due-trials |
Completed, but no date Terminated | 2020-001528-32 | Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals Studio randomizzato adattivo per la terapia della malattia da Corona virus 2019 a casa con antivirali... | bad-data | |
Not reported Terminated | 2021-000243-50 | Understanding the Impact of HIV-DNA resistance mutations detected by NGS in Simplification strategies to 2-Drug Regimens for patients virologically suppressed with previous failures and/or previous re... | 2024-02-28 | due-trials |
Completed, report not yet due | 2021-004188-28 | Adaptative, Phase IV Randomized, Open-label, Multicenter Study to Determine the Safety and Efficacy of different MONoclonal Antibodies (MoAbs) to SARS-CoV-2 for the Early Treatment of COVID-19 in Non-... | 2025-01-15 | not-yet-due |
Completed, report not yet due Terminated | 2021-006495-16 | Immunogenicity and safety of Sotrovimab (Vir 7831) IV as primary prophylaxis in anti-SARS-CoV-2 vaccine non responders Immunogenicità e sicurezza di Sotrovimab (Vir 7831) IV come profilassi primari... | 2024-12-02 | not-yet-due |
Other | 2022-000905-29 | Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies Cinetica tempoRale de... | not-yet-due | |
Other | 2022-001819-12 | Cysteamine in association with standard therapy for the treatment of hospitalized patients with COVID-19 pneumonia: phase 2 study on safety of a new antiviral and direct therapy on the host Cisteam... | not-yet-due |